Siponimod intolerance

Kirchheiner J et al. (2003) Influence of CYP2C9 genetic polymorphisms on pharmacokinetics of celecoxib and its metabolites.

Ross KA et al. (2010) Worldwide allele frequency distribution of four polymorphisms associated with warfarin dose requirements.

Speed WC et al. (2009) Global variation in CYP2C8-CYP2C9 functional haplotypes.

Maekawa K et al. (2006) Four novel defective alleles and comprehensive haplotype analysis of CYP2C9 in Japanese.

None (2001) Racial differences in the response to drugs--pointers to genetic differences.

Sullivan-Klose TH et al. (1996) The role of the CYP2C9-Leu359 allelic variant in the tolbutamide polymorphism.

Steward DJ et al. (1997) Genetic association between sensitivity to warfarin and expression of CYP2C9*3.

Gray IC et al. (1995) A 2.4-megabase physical map spanning the CYP2C gene cluster on chromosome 10q24.

Li T et al. (2006) Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

Sanderson S et al. (2005) CYP2C9 gene variants, drug dose, and bleeding risk in warfarin-treated patients: a HuGEnet systematic review and meta-analysis.

King BP et al. (2004) Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.

Fichtlscherer S et al. (2004) Inhibition of cytochrome P450 2C9 improves endothelium-dependent, nitric oxide-mediated vasodilatation in patients with coronary artery disease.

Gough SM et al. (2003) Refined physical map of the human PAX2/HOX11/NFKB2 cancer gene region at 10q24 and relocalization of the HPV6AI1 viral integration site to 14q13.3-q21.1.

Williams PA et al. (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin.

Higashi MK et al. (2002) Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy.

Leung AY et al. (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients.

Xie HG et al. (2001) Molecular basis of ethnic differences in drug disposition and response.

Aithal GP et al. (2000) Relationship of polymorphism in CYP2C9 to genetic susceptibility to diclofenac-induced hepatitis.

Thum T et al. (2000) Gene expression in distinct regions of the heart.

Kidd RS et al. (1999) Pharmacokinetics of chlorpheniramine, phenytoin, glipizide and nifedipine in an individual homozygous for the CYP2C9*3 allele.

Aithal GP et al. (1999) Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.

et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data.

Kohn MH et al. (2000) A gene-anchored map position of the rat warfarin-resistance locus, Rw, and its orthologs in mice and humans.

Tate SK et al. (2005) Genetic predictors of the maximum doses patients receive during clinical use of the anti-epileptic drugs carbamazepine and phenytoin.